ERCC1 and melanoma: Additionally, one of the investigated catechol-based inhibitors of ERCC1-XPF (13 compound) displayed high activity in NER and selectivity against deoxyribonuclease I and Flap structure-specific endonuclease 1 (FEN-1), which resulted in enhanced cisplatin activity in A375 melanoma cells [92].